Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion

Weihua Guan, Anna Kozak, Azza B. El-Remessy, Maribeth H Johnson, Bindu A. Pillai, Susan C. Fagan

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

We have shown that reduction of blood pressure (BP) immediately after the onset of reperfusion reduced neurovascular damage and improved functional outcome after experimental cerebral ischemia and candesartan is particularly effective in improving long-term functional outcome. In this study, we sought to determine if early BP lowering with candesartan, in the presence of an occluded cerebral artery, will reduce injury and improve outcome after experimental stroke. Male Wistar rats underwent 24 h or 7 days of middle cerebral artery occlusion (MCAO). A single dose of 1 mg/kg candesartan was administered intravenously at 3 h after MCAO. Animals received neurobehavioral testing at 3 h, 24 h, and 7 days, and blood pressure was measured by telemetry. Animals had brain tissue collected for infarct size (24 h and 7 days), hemoglobin content, matrix metalloproteinase (MMP) activity, and vascular endothelial growth factor (VEGF) expression (24 h only). Candesartan significantly decreased blood pressure, infarct size (-20%; p = 0.021), hemoglobin excess (-50%; p = 0.0013), and edema (-35%; p = 0.0005) at 24 h after MCAO. This resulted in a reduced cerebral perfusion deficit (p = 0.034) in the ischemic hemisphere compared with saline and significantly improved Bederson scores and paw grasp. MMP-2, MMP-9, and VEGF were significantly increased by MCAO, but there were no differences between candesartan- and saline-treated animals. There were no significant differences in behavioral outcome at day 7. BP lowering with candesartan reduces early brain injury after experimental stroke even when the artery remains occluded. The early benefits were not sustained at 7 days, as seen in reperfused animals, however. The neuroprotection and neurorestorative properties of candesartan may occur by separate distinct mechanisms.

Original languageEnglish (US)
Pages (from-to)179-185
Number of pages7
JournalTranslational Stroke Research
Volume2
Issue number2
DOIs
StatePublished - Jun 1 2011

Fingerprint

Middle Cerebral Artery Infarction
Wounds and Injuries
Blood Pressure
Vascular Endothelial Growth Factor A
Hemoglobins
Stroke
Telemetry
Cerebral Arteries
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Hand Strength
candesartan
Brain Ischemia
Matrix Metalloproteinases
Brain Injuries
Reperfusion
Wistar Rats
Edema
Arteries
Perfusion

Keywords

  • Blood pressure
  • Candesartan
  • Reperfusion
  • Stroke

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion. / Guan, Weihua; Kozak, Anna; El-Remessy, Azza B.; Johnson, Maribeth H; Pillai, Bindu A.; Fagan, Susan C.

In: Translational Stroke Research, Vol. 2, No. 2, 01.06.2011, p. 179-185.

Research output: Contribution to journalArticle

Guan, Weihua ; Kozak, Anna ; El-Remessy, Azza B. ; Johnson, Maribeth H ; Pillai, Bindu A. ; Fagan, Susan C. / Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion. In: Translational Stroke Research. 2011 ; Vol. 2, No. 2. pp. 179-185.
@article{81322d4a374e402b8a4ade0b5875977e,
title = "Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion",
abstract = "We have shown that reduction of blood pressure (BP) immediately after the onset of reperfusion reduced neurovascular damage and improved functional outcome after experimental cerebral ischemia and candesartan is particularly effective in improving long-term functional outcome. In this study, we sought to determine if early BP lowering with candesartan, in the presence of an occluded cerebral artery, will reduce injury and improve outcome after experimental stroke. Male Wistar rats underwent 24 h or 7 days of middle cerebral artery occlusion (MCAO). A single dose of 1 mg/kg candesartan was administered intravenously at 3 h after MCAO. Animals received neurobehavioral testing at 3 h, 24 h, and 7 days, and blood pressure was measured by telemetry. Animals had brain tissue collected for infarct size (24 h and 7 days), hemoglobin content, matrix metalloproteinase (MMP) activity, and vascular endothelial growth factor (VEGF) expression (24 h only). Candesartan significantly decreased blood pressure, infarct size (-20{\%}; p = 0.021), hemoglobin excess (-50{\%}; p = 0.0013), and edema (-35{\%}; p = 0.0005) at 24 h after MCAO. This resulted in a reduced cerebral perfusion deficit (p = 0.034) in the ischemic hemisphere compared with saline and significantly improved Bederson scores and paw grasp. MMP-2, MMP-9, and VEGF were significantly increased by MCAO, but there were no differences between candesartan- and saline-treated animals. There were no significant differences in behavioral outcome at day 7. BP lowering with candesartan reduces early brain injury after experimental stroke even when the artery remains occluded. The early benefits were not sustained at 7 days, as seen in reperfused animals, however. The neuroprotection and neurorestorative properties of candesartan may occur by separate distinct mechanisms.",
keywords = "Blood pressure, Candesartan, Reperfusion, Stroke",
author = "Weihua Guan and Anna Kozak and El-Remessy, {Azza B.} and Johnson, {Maribeth H} and Pillai, {Bindu A.} and Fagan, {Susan C.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s12975-010-0061-1",
language = "English (US)",
volume = "2",
pages = "179--185",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "2",

}

TY - JOUR

T1 - Acute Treatment with Candesartan Reduces Early Injury After Permanent Middle Cerebral Artery Occlusion

AU - Guan, Weihua

AU - Kozak, Anna

AU - El-Remessy, Azza B.

AU - Johnson, Maribeth H

AU - Pillai, Bindu A.

AU - Fagan, Susan C.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - We have shown that reduction of blood pressure (BP) immediately after the onset of reperfusion reduced neurovascular damage and improved functional outcome after experimental cerebral ischemia and candesartan is particularly effective in improving long-term functional outcome. In this study, we sought to determine if early BP lowering with candesartan, in the presence of an occluded cerebral artery, will reduce injury and improve outcome after experimental stroke. Male Wistar rats underwent 24 h or 7 days of middle cerebral artery occlusion (MCAO). A single dose of 1 mg/kg candesartan was administered intravenously at 3 h after MCAO. Animals received neurobehavioral testing at 3 h, 24 h, and 7 days, and blood pressure was measured by telemetry. Animals had brain tissue collected for infarct size (24 h and 7 days), hemoglobin content, matrix metalloproteinase (MMP) activity, and vascular endothelial growth factor (VEGF) expression (24 h only). Candesartan significantly decreased blood pressure, infarct size (-20%; p = 0.021), hemoglobin excess (-50%; p = 0.0013), and edema (-35%; p = 0.0005) at 24 h after MCAO. This resulted in a reduced cerebral perfusion deficit (p = 0.034) in the ischemic hemisphere compared with saline and significantly improved Bederson scores and paw grasp. MMP-2, MMP-9, and VEGF were significantly increased by MCAO, but there were no differences between candesartan- and saline-treated animals. There were no significant differences in behavioral outcome at day 7. BP lowering with candesartan reduces early brain injury after experimental stroke even when the artery remains occluded. The early benefits were not sustained at 7 days, as seen in reperfused animals, however. The neuroprotection and neurorestorative properties of candesartan may occur by separate distinct mechanisms.

AB - We have shown that reduction of blood pressure (BP) immediately after the onset of reperfusion reduced neurovascular damage and improved functional outcome after experimental cerebral ischemia and candesartan is particularly effective in improving long-term functional outcome. In this study, we sought to determine if early BP lowering with candesartan, in the presence of an occluded cerebral artery, will reduce injury and improve outcome after experimental stroke. Male Wistar rats underwent 24 h or 7 days of middle cerebral artery occlusion (MCAO). A single dose of 1 mg/kg candesartan was administered intravenously at 3 h after MCAO. Animals received neurobehavioral testing at 3 h, 24 h, and 7 days, and blood pressure was measured by telemetry. Animals had brain tissue collected for infarct size (24 h and 7 days), hemoglobin content, matrix metalloproteinase (MMP) activity, and vascular endothelial growth factor (VEGF) expression (24 h only). Candesartan significantly decreased blood pressure, infarct size (-20%; p = 0.021), hemoglobin excess (-50%; p = 0.0013), and edema (-35%; p = 0.0005) at 24 h after MCAO. This resulted in a reduced cerebral perfusion deficit (p = 0.034) in the ischemic hemisphere compared with saline and significantly improved Bederson scores and paw grasp. MMP-2, MMP-9, and VEGF were significantly increased by MCAO, but there were no differences between candesartan- and saline-treated animals. There were no significant differences in behavioral outcome at day 7. BP lowering with candesartan reduces early brain injury after experimental stroke even when the artery remains occluded. The early benefits were not sustained at 7 days, as seen in reperfused animals, however. The neuroprotection and neurorestorative properties of candesartan may occur by separate distinct mechanisms.

KW - Blood pressure

KW - Candesartan

KW - Reperfusion

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=79955740049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955740049&partnerID=8YFLogxK

U2 - 10.1007/s12975-010-0061-1

DO - 10.1007/s12975-010-0061-1

M3 - Article

C2 - 21904593

AN - SCOPUS:79955740049

VL - 2

SP - 179

EP - 185

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 2

ER -